Mechanism of White Matter Injury and Promising Therapeutic Strategies of MSCs After Intracerebral Hemorrhage

Jing Li¹, Linglong Xiao¹, Dian He¹, Yunhao Luo² and Haitao Sun¹,²,³*

¹Neurosurgery Center, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, The Neurosurgery Institute of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou, China; ²Division of Laboratory Medicine, Clinical Biobank Center, Microbiome Medicine Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China; ³Key Laboratory of Mental Health of The Ministry of Education, Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Southern Medical University, Guangzhou, China

Intracerebral hemorrhage (ICH) is the most fatal subtype of stroke with high disability and high mortality rates, and there is no effective treatment. The predilection site of ICH is in the area of the basal ganglia and internal capsule (IC), where exist abundant white matter (WM) fiber tracts, such as the corticospinal tract (CST) in the IC. Proximal or distal white matter injury (WMI) caused by intracerebral parenchymal hemorrhage is closely associated with poor prognosis after ICH, especially motor and sensory dysfunction. The pathophysiological mechanisms involved in WMI are quite complex and still far from clear. In recent years, the neuroprotection and repairment capacity of mesenchymal stem cells (MSCs) has been widely investigated after ICH. MSCs exert many unique biological effects, including self-recovery by producing growth factors and cytokines, regenerative repair, immunomodulation, and neuroprotection against oxidative stress, providing a promising cellular therapeutic approach for the treatment of WMI. Taken together, our goal is to discuss the characteristics of WMI following ICH, including the mechanism and potential promising therapeutic targets of MSCs, aiming at providing new clues for future therapeutic strategies.

Keywords: intracerebral hemorrhage, white matter injury, mesenchymal stem cells, corticospinal tract, cell therapy

INTRODUCTION

Intracerebral hemorrhage (ICH) is triggered by the spontaneous rupture of blood vessels, wherein the blood constituents penetrate the brain parenchyma following a path of least resistance and thus destroy both gray and white matter (GM and WM) structures (Qureshi et al., 2009). ICH is the most lethal form of stroke characterized by high morbidity, high disability, and high mortality with no
effective treatment. It was demonstrated that more than 77% of ICH patients suffered WM injury (WMI), and a better understanding of WMI and remyelination may shed new light on the treatment of ICH (Smith et al., 2004).

Damage to WM fibers which establish connections among different regions impairs brain connectivity, leading to functional deficits. Dysfunction following cerebral parenchymal hemorrhage derives not only from neuron or synapse losses, but also from primary damage to the WM axons. The area of the basal ganglia where abundant WM fiber tracts cross is the predominant location of hematomata in human ICH. The internal capsule (IC), which lies between the putamen (embraced in the basal ganglia) and the thalamus, contains both descending and ascending fiber bundles conducting sensory, motor, and visual information. Once bleeding occurs in this region, the physiological structure and function of the WM are interrupted to varying degrees, leading to various complications and dysfunctions, such as hemiplegia, hemianopia, hemidysesthesia, and aphasia (Kusano et al., 2009; Balami and Buchan, 2012; Keep et al., 2012; Wu et al., 2017). The corticospinal tracts (CSTs) and corticothalamic tracts’ damage can cause contralateral hemiplegia. Destruction of the optic radiation following deep basal ganglia ICH leads to hemianopia, while hemidysesthesia is caused due to lesions of the central thalamic radiations. It is worth mentioning that IC injury can present all these three clinical manifestations resulting in serious sensorimotor dysfunction in human ICH. WMI is considered the major cause of motor-sensory disorders commonly seen in ICH patients. Therefore, reducing WM or repairing WM after ICH is critical for reducing long-term neurological deficits, especially for motor function recovery.

In the past few decades, stem cell therapy has been actively explored for the treatment of stroke. Mesenchymal stem cells (MSCs) are pivotal to tissue homeostasis, repair, and regeneration for their self-renewing and multipotent characteristics, which are emerging as the most promising means of allogeneic cell therapy. Basic and clinical research clarify that MSCs are not antigen-presenting cells and would not cause activation of the host’s immune system (Tse et al., 2003). These cells can be harvested and expanded from a variety of adult and perinatal tissues, such as bone marrow, adipose tissue, peripheral blood, fetal tissues, umbilical cord tissues, and placental tissues. The neuroprotection and repairment capacity of MSCs has been widely investigated after ICH. MSCs exert many unique biological effects in tissue replacement, neurotroph, neurogenesis, angiogenesis, anti-apoptosis, and immunomodulation (Caplan and Dennis, 2006; Mine et al., 2013; Galipeau and Sensebe, 2018; Song et al., 2020), which provides a promising therapeutic strategy in the treatment of WMI. MSCs participate in both innate immunity and adaptive immunity. Their immunomodulatory functions are exerted mainly via the release of bioactive factors and interactions with immune cells, which then change the damaged microenvironment by shifting the balance from toxic to protective regenerative events.

Herein, this review is primarily focused on the pathophysiology and onset mechanism of post-ICH WMI and potential therapy methods of MSCs, in hopes that it can benefit clinical treatment.

COMPOSITION AND THE MAIN FUNCTION OF BRAIN WM

White matter comprises over 40% of the total volume of adult brain tissue and takes an indispensable part in distributed neural networks that are responsible for neurobehavioral management (Bedell and Narayana, 1998; Herndon et al., 1998). The two main parts- myelinated axon tracts and supporting glial cells including oligodendrocytes (OLs), astrocytes, and microglia- are embraced in WM. The axons (nerve fibers) are surrounded by multiple dense myelin membranes produced by mature OLs (Kang and Yao, 2019), the molecular structure integrity of which makes axons insulated from each other, thus promising the quick and efficient conduction of electrical nerve impulses (transmitting the action potentials) and protecting the nerve fibers from injury (Roncaglio et al., 2006).

Specifically, three parts constitute WM fiber bundles: projection tracts, commissural tracts, and association tracts (Gerrish et al., 2014). Projection tracts transmit nerve signals from the cortex to other regions of the central nervous system (CNS) (Ge et al., 2002). For instance, CST is the dominant pathway responsible for conveying descending information from the cerebral cortex to the spinal cord. The commissural tracts allow the communication between the left and right cerebral hemispheres (Ge et al., 2002). The association tracts build up connections among cortical lobes within the ipsilateral hemisphere. All these tracts form networks between different regions and serve diverse functions (Ge et al., 2002). Up to now, a large amount of research has clarified the brain functions associated with WM, such as cognitive function, motor function, reading, and practicing abilities (Schmahmann et al., 2008; Carreiras et al., 2009).

PATHOPHYSIOLOGY OF WMI AFTER ICH

The pathophysiology change of WMI after ICH is mainly characterized by demyelination, axonal injury, and death of OLs. OLs are the sole source of myelin in the adult CNS, and generally form insulating myelin sheaths marked by myelin basic protein (MBP), enhancing the propagation of action potentials and supporting neuronal and axonal integrity through metabolic coupling under physical circumstances (Bacmeister et al., 2020). OLs contain a high level of iron and are especially sensitive to iron overload, which makes them quite vulnerable to hemorrhagic insults; meanwhile, missed OLs leave axons susceptible to degeneration (Windrem et al., 2020). With the degradation of hemoglobin released from dead erythrocytes, there is a sharp increase in intracellular Fe^{2+} destroying OLs, and iron chelator can inhibit this oxidative toxicity in OLs. Both apoptosis and necrosis are involved in the mechanism of OLs loss. With the onset of ICH, OLs’ expression of caspase-3 in the lesion increases and most of the damaged cells undergo necrosis. Mitochondrial dysfunction is also attributed to OLs apoptosis. Fortunately, OLs maintain the capacity of regeneration and repair after damage to the CNS. OLs death is accompanied by oligodendrocyte progenitor cells (OPCs) proliferation during...
the acute period in the perihematomal WMI, which is responsible for generating new OLs to remyelinate denuded axons and reconstruct neuronal function.

Dramatrical demyelination and axonal damage were first observed at the perihematomal site within three days after ICH, and the axonal damage gradually extended to the adjacent parenchyma over time (Wasserman and Schlichter, 2008). These pathologic changes are highly related to brain edema and neurologic dysfunction, indicating that WMI plays a critical role in neurologic impairment. Hijioka et al. (2016) has investigated the exact relationship between axon pathology and impaired sensorimotor functions; the former mainly referred to axonal transport deficits and structural destruction. The axonal dysfunction in the IC was confirmed to be strongly linked with early motion disturbance after ICH in mice (Hijioka et al., 2016). Remyelination and axonal regeneration are considered valid repair forms in WMI (Joseph et al., 2016). Remyelination is defined as adult OPCs differentiating into new myelin-forming OLs in a regenerative process after CNS demyelination (Gensert and Goldman, 1997; Fancy et al., 2004; Kang and Yao, 2019).

To successfully regenerate, damaged axons must reseal denuded stumps, rebuild the cytoskeleton, coligate and transport building substrates, package axon modules, and form growth cones, which is a highly energy-demanding process (Bradke et al., 2012; Lu et al., 2014; He and Jin, 2016). Based on this, Han et al. (2020) raised the “energy deficit” definition and proved that enhancing mitochondrial transport and energetic metabolism can dramatically stimulate axonal regeneration, promoting functional restoration in a spinal cord injury (SCI) animal model. Ultrastructural features of collagenase-induced ICH have been systematically examined in mice over time (Li et al., 2018). Obvious axonal demyelination and degeneration, and the presence of dystrophic neurites in the axons, were demonstrated but OLs proliferation was also observed, which is responsible for the myelination of axons (Li et al., 2018). They first showed a robust inflammatory response of erythropagocytes by microglia and macrophages after ICH by transmission electronic microscope (TEM) (Li et al., 2018). Myelination could also be regulated by the growth factor neuregulin (NRG) through binding to the transmembrane tyrosine kinase receptors (ErbB) on unsheathing OLs. Collectively, severe changes of myelin destruction and swelling axons are clear in the ICH animal models, but the exact mechanisms contributing to the loss of motor function are uncertain.

**PATHOPHYSIOLOGY MECHANISM OF WMI AFTER ICH**

The influx of blood from vessels into the brain destroys GM and WM. Increasing studies have focused on the implicated pathophysiology of WMI after ICH (Wasserman and Schlichter, 2008; Gerrish et al., 2014; Chen W. et al., 2019; Chen Z. et al., 2019). It is demonstrated that the mass effect and barotrauma during hematoma formation present immediate compression of adjacent brain tissue the moment of ICH onset, which is defined as the primary brain injury. Soon afterward, secondary brain injury- excitotoxicity, oxidative stress, and neuroinflammation- aggravate the WMI leading to neurological deterioration (Aronowski and Zhao, 2011; Babu et al., 2012; Duan et al., 2016; Lan et al., 2017b), accompanied by a succession of pathologic changes which contain hemodynamic changes resulted from ischemia, increased cerebral edema, disruption of the blood–brain barrier (BBB) function, effects of erythrocytes decomposition products, and apoptosis (Aronowski and Zhao, 2011; Keep et al., 2012; Zhou et al., 2014; Chen S. et al., 2015). And it was shown that intracerebral hematoma extended via perivascular spaces and the perineurium (Yin et al., 2013). All these pathologic changes make the nerve fibers within the hematoma lesion distend, distort, and finally disrupt to a point at which they cannot be rescued (Figure 1). Those located in the perihematomal, meanwhile, exert varying degrees of impairment, exactly where researchers continuously focus on and try to intervene.

**Immune Inflammatory Response**

Complex immune and inflammatory cascades characterized by the mobilization and activation of inflammatory molecules are triggered at the moment the blood composition is released into the substance, which plays a pivotal role in ICH-induced brain injury (Lan et al., 2017b), especially during the secondary WMI. The primary and secondary damage usually mutually affect the whole developing process. The leakage of BBB after ICH is mainly derived from endothelial cell activation and vascular ONOO− formation, leading to the reduction of key tight junction proteins which generally promise the BBB permeability such as claudin-5, occludin, and zonula occludens (ZO)-1 (Abbott et al., 2010). There is increasing evidence that an inflammatory response can promote the formation of edema by increasing the BBB permeability near the hematoma, thereby aggravating the mass effect, enhancing the process of cell death through secondary ischemia, and further causing inflammatory damage to the surrounding brain tissue (Chu et al., 2014; Wang T. et al., 2015). Many inflammatory cells have been demonstrated to be involved and work in concert to modulate the inflammatory response both in ischemic stroke and ICH. Herein, we introduce several immune cells involved in inflammation in detail as follows.

**Microglia**

Microglia, the resident myeloid phagocytes in the brain parenchyma, constantly and rapidly monitor the brain microenvironment for threats and damage and play a critical role in maintaining homeostasis in the brain by removing pathogens and injured brain tissue debris, and reconstructing the extracellular matrix and synapses, just like a “cop.” When encountered with ICH, they can be activated within minutes and migrate to the lesion together with peripheral macrophages (Lan et al., 2017b), and become highly phagocytic to respond to factors secreted by necrotic neurons or astrocytes, like adenosine triphosphate (ATP), galactin-3, or high mobility group box 1 (HMGB1), which are all embraced in damage-associated molecular pattern molecules (DAMPs, also known as alarmins) (Kong and Le, 2011; Ohnishi et al., 2011; Fang et al., 2013; Zhou et al., 2014; Xiao et al., 2020). Meanwhile,
microglia cells secrete multiple cytokines and chemokines associated with the axon-glial injury via the transcription factor nuclear factor-κB (NF-κB), and show enhanced phagocytosis, thereby aggravating structural WMI. DAMPs can initiate the activation of microglia via several toll-like receptors (TLRs) in the neuroinflammatory processes after ICH. The TLR4 on microglia cell surfaces generally interacts with TRIF and MyD88, and then the information is passed through downstream NF-κB, like phosphorylated P65, and several other secreted proinflammatory factors, causing inflammation (Zhou et al., 2014; Lan et al., 2017a). It was proven that traumatic brain injury (TBI) could induce a rapid and persistent up-regulation of Myd88, NF-κB, and proinflammatory cytokines (Ling et al., 2013). Microglial activation can also be induced by thrombin and complement factors via protease-activated receptors (PARs). A newly found adenosine diphosphate (ADP)/ATP-responsive G-protein coupled receptor, P2Y12, helps microglia migrate to the site of injury (Suzuki et al., 2020). Subsequently, microglia cells in an activated state and the toxic molecules secreted further destroy the BBB, leading to peripheral immune cells’ infiltration, thus propagating inflammatory damage.

According to the surface markers and intracellular cytokines expressed, microglia can be polarized into classically activated (M1, pro-inflammatory, and neurotoxic) and alternatively activated (M2, anti-inflammatory, and neuroprotective) phenotypes (Zhang et al., 2017). That the microglia can dynamically and temporally change their phenotypes in response to acute brain injury is exactly the pointcut of brain damage intervention researchers pay attention to. M1 microglia could release high levels of proinflammatory cytokines, that, in turn, hinder axonal regeneration and OLs maturation (Lampron et al., 2015; Chen et al., 2017; Qin et al., 2017). In contrast, polarized M2 microglia typically secrete restorative cytokines and growth factors, remove tissue debris through phagocytosis, and promote...
remyelination (Olah et al., 2012; Zhao et al., 2015). It was proven that activated microglia act as a double-edged sword and the transfer of M1 to M2 can dramatically alleviate the brain injury caused by inflammation (Zhao et al., 2019).

Astrocytes

Astrocytes are recognized as active elements of the brain circuitry, and play key roles in maintaining homeostasis of the extracellular environment, including neurotrophic and structural supporting functions, stabilization of cell–cell communications, and anti-oxidative stress functions (Ransom and Ransom, 2012). Activated astrocytes usually respond to CNS disorders through reactive astrogliosis which represent a series of successive processes including changes of gene and protein expression, proliferation and migration of cells, cellular hypertrophy, and formation of glial scars. Some research demonstrated that reactive astrocytes generate neurotrophic factors (NTFs), isolate injured sites, and prevent harmful inflammation. Whereas it was shown that astrocytes could restrain axonal regeneration and hamper other repair processes in the brain by expressing a wide range of molecules as demonstrated in an earlier study (McKeon et al., 1991). Moreover, axonal regeneration and the reconnection among neurons are further inhibited by the resulting glial scar, inhibiting the formation of which does not always alleviate tissue damage in animal experiments (Wanner et al., 2013; Cregg et al., 2014).

T Lymphocytes

Lymphocytes play a vital role in immune surveillance and homeostasis maintenance in the peripheral system, among which T cells mainly participate in adaptive cellular immunity. CD4+ T cells dominate the lymphocyte population whether in autoblood- or collagenase-induced ICH models, while CD8+ T cells constitute an extremely small infiltrating leukocyte population. Undisputedly, FoxP3+CD4+ regulatory T cells (Tregs) are the major immunosuppressive lineage of the CD4+ T cell compartment. It is generally supposed that T cells rarely enter the brain parenchyma except when pathologic changes occur, and only when the stroke onset, T cells would migrate largely and infiltrate into the lesion site following the activation of microglia (Ito et al., 2019).

Recent research demonstrated that it was the regulatory T cells inside the brain that exerted robust neuronal protection in ischemic stroke by suppressing neurotoxic astrogliosis through producing epidermal growth factor receptor (EGFR) ligand (Ito et al., 2019). This finding suggests that, in the repair of the ICH process, the function of brain T cells should also be highly focused on. Apart from sustaining immune tolerance (Sakaguchi et al., 2010; Lowther and Hafler, 2012), Tregs perform specialized functions in tissue homeostasis and remodeling mainly through restraining the activation and release of cytokines (Liesz et al., 2009; Ito et al., 2019). IL-10 originating from Tregs can trigger hemoglobin-activated microglia/macrophages toward the M2 phenotype. Similarly, it was indicated that Tregs protected against ICH-induced inflammatory injury by modulating microglia/macrophages polarization through the IL-10/GSK3β/PTEN axis which might exert importance in Treg-induced microglia polarization (Zhou et al., 2017). When co-cultured in vitro, Tregs also changed the polarization of microglia, decreased the expression of MHC-II, IL-6, and TNF-α, and increased expression of CD206.

CCR5 participates in the regulation of T cells and monocytes/macrophage lines’ migration, mainly expressed on the T cells at rest, monocytes, and immature dendritic cells (Joy et al., 2019). Also, accumulating evidence highlighted a central role for mTOR as a fundamental determinant of cell fate in antigen-activated CD4+ T cells. It was shown that suppression of activity in the Akt/mTOR pathway impaired Th17 and Th1 differentiation and promoted the development of Tregs. Fingolimod is recognized as an inhibitor of peripheral immune cell infiltration and can reduce inflammatory injury after ICH (Wei et al., 2011; Fu et al., 2014). These results demonstrated that the number of protective Tregs in the CNS was reduced when the infiltrating inflammatory cells were non-specifically inhibited. It was proven that the transfer of protective Tregs attenuated neurological deficit after ICH.

Oxidative Stress

Oxidative stress initiated by the blood breakdown component or factors of the plasma plays a central role in the pathogenesis of WMI. Hemolysis after ICH is not that rapid. Rather, the main component of hematoma-erythrocytes starts to lyse 1 day after ICH and continues over days to weeks, followed by the release of decomposition products, including hemoglobin (Hb), heme, and iron, which exert neurotoxic effects on the lesion site and perihematomal regions (Cao et al., 2016). These metabolites, on the one hand, cause consecutive oxidative reactions; on the other hand, they can trigger inflammatory reaction via TLRs. Iron is derived from the collapse of heme by hemeoxygenase (HO)-1 and HO-2. Iron mediates neuronal ferroptosis, generating reactive oxygen species (ROS) and turning Fe^{2+} into Fe^{3+} via the Fenton reaction (Hu et al., 2016). ROS also mediates the inflammatory cascade, giving rise to cell death and perihematomal swelling, which finally leads to WMI.

Neurotoxicity Mediated by Glutamate

In addition to increased ROS and oxidative stress, the levels of extracellular glutamate can also be augmented after ICH. It was confirmed followed by an increase of oxidative stress leading to sustained neuronal loss that ICH-induced striatal lesion produces distinct changes of EAAT1 and EAAT2 glutamate transporters expression and glutamate uptake activity. Besides, the level of perihematomal glutamate is highly related to the outcome in clinical ICH patients (Wu et al., 2013). It was demonstrated that in hemiplegic patients with basal ganglia bleeding affecting the IC, the earlier mini surgery was conducted, the less glutamate existing in peri-hematoma and the better prognosis, which means the level of glutamate is highly correlated with the outcome of ICH (Wu et al., 2013). Several pieces of research showed blood glutamate grabbing was effective at lessening the excitotoxicity of extracellular glutamate released during ischemic brain injury, although this did seemingly occur
in ICH (Castillo et al., 2016; da Silva-Candal et al., 2018). It was indicated that blood glutamate grabbing cannot reduce the hematoma but still can serve as a safe excitotoxic treatment modality following ICH.

FUNCTIONS AND POSSIBLE MECHANISMS OF MSCs
TRANSPLANTATION TARGETING WMI AFTER ICH

Ongoing research efforts are confirming our acknowledgment of the robust potential applications in regenerative medicine of stem cells (Chen et al., 2008), the therapeutic effectiveness of which has been reported in numerous previous experiments conducted in animal models of ICH. Among various stem cells, the multipotency and self-renewal capacity make MSCs a promising candidate for WMI treatment (Ramos-Cabrera et al., 2010; Huang et al., 2013; Mine et al., 2013), which can be expatiated as many unique biological effects including self-recovery by producing growth factors and cytokines, regenerative repair, inherent immunomodulation, and neuroprotection against oxidative stress, and can be further engineered to enhance immunomodulatory functions (Caplan and Dennis, 2006; Lee et al., 2014; Galipeau and Sensebe, 2018; Song et al., 2020), etc.

Promoting Self-Recovery and Regenerative Repair

The organism itself possesses a few endogenous mechanisms, such as migration of endogenous stem cells and hematoma clearance, which benefit the repair of injured WM structures. Transplanting exogenous stem cells also exerts significant neuroprotection on ICH although the difficulty in obtainment limits their clinical applications. Other sources of stem cells are required for replacement therapy and MSCs rise in response to the proper time and conditions. MSCs can secrete many trophic molecules when transferred into the body generally by two approaches-orthotopic transplantation and caudal vein transplantation (Smith and Gavins, 2012; Shichinohe et al., 2015)- thus promoting endogenous repair mechanism, which eventually accelerates functional recovery after stroke.

Mesenchymal stem cells transplantation is promising in terms of angiogenesis. Pfeiffer et al. (2019) found human amnion-derived MSCs (hAMSCs), well-known for their favorable angiogenic potential, enhanced human placental endothelial cells (hPEC) viability, and network formation of endothelial cells (Konig et al., 2015) and promoted angiogenesis in vivo (Kinzer et al., 2014; Tuca et al., 2016; Ertl et al., 2018). Brain-derived neurotrophic factor (BDNF), as the most abundant neurotrophin in the CNS, can promote neurogenesis, oligodendrocyte genesis, myelination, and synaptic plasticity through interaction with protein tropomyosin receptor kinase B (TrkB), which is also a receptor of neurotrophin-4 (NT4) (Tolar et al., 2010; Lim et al., 2011). Recently, given the fact that TrkB usually can’t be expressed by the MSCs in an undifferentiated state and the capacity of EA in promoting neurofunctional recovery through specific NTFs, such as VEGF, BDNF, and NT4 (Ahn et al., 2016), investigators combined the electroacupuncture (EA) with genetically modified TrkB gene-transfected MSCs (TrkB-MSCs) in a mouse model of ischemic stroke (Ahn et al., 2019). Consistent with the original assumption, the results showed the combination facilitated further neural survival and differentiation via stimulating the BDNF/NT4-TrkB signaling pathway rather than simply the administration of MSCs (Ahn et al., 2019). EA could directly stimulate the proliferation and differentiation of endogenous neural NSC in a rat model of ischemic stroke (Tan et al., 2018). BDNF can also exert neurotrophic effects on neuronal survival and neurite outgrowth, particularly the CST axons (Gupta et al., 2009). This procedure can be mediated by growth-associated protein-43 (GAP-43) which is highly distributed in the presynaptic membrane associated with neurite extension and long-term synaptic enhancement (Ramakers et al., 2000; Gupta et al., 2009; Morita and Miyata, 2013). Cui et al. (2017) elaborated that MSC grafted increased GAP-43 expression via the ERK1/2 and pro-survival phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways after transplanting BMSC into a rat model of...
| Diseases model       | Model animals | Origin of MSCs | Treatment route | Dose       | Functions                                                                 | Mechanisms                                                                 | References                      |
|---------------------|---------------|---------------|----------------|------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------|---------------------------------|
| ICH (collagenase I) | Wistar rats (270–320 g) | BMSCs, passage 3 | Intracerebral injection (right striatum) | $5.0 \times 10^5$ cells | Improved functional deficits and reduced lesion volume | BMSCs decreased apoptotic cells | Yang et al. (2011) |
| MCAO                | Male Balb/c mice (8 W) | BMSCs, passage 3 | Intracerebral injection | $2.0 \times 10^5$ cells | Promoted regeneration of the infarcted brain | BMSCs triggered endogenous signaling pathways of survival and repair in neurons by secreting soluble neurotrophic factors | Shichinohe et al. (2015) |
| MCAO                | Male C57BL/6J mice (5 and 8 W) | BMSCs, passage 3 | Intracerebral injection (peri-infarct site) | $1.0 \times 10^6$ cells | Improved stroke-associated motor and cognitive dysfunction | EA combined with grafted TrkB-MSCs stimulated the BDNF/NT4-TrkB signaling pathway | Ahn et al. (2019) |
| ICH (autologous arterial blood) | Adult male SD rats (250–280 g) | BMSCs (femurs of 21-day-old male SD rats, passage 4) | Intravenous injection (retro-orbital) | NA | Neuroprotective effects: attenuated neurological deficits and activated axonal regeneration | BMSCs increases of GAP-43 expression through ERK1/2 and PI3K/Akt activation | Cui et al. (2017) |
| ICH (collagenase IV) | Adult male SD rats (250–350 g) | hPD-MSCs | Intravenous injection (tail vein) | $1.0 \times 10^6$ cells | Improve neurological recovery; prevent hematoma expansion in the hyperacute stage of ICH and decrease acute mortality | MSCs increased the expression of tight junction proteins associated with the enhancement of cerebrovascular integrity | Choi et al. (2018) |
| MCAO                | Adult male Wistar rats (270–300 g) | HP-BMSCs (femurs and tibias of 2-week-old Wistar rats) | Intravenous injection (tail vein) | $1.0 \times 10^6$ cells | Promoted locomotion recovery; enhanced angiogenesis and neurogenesis | Hypoxic preconditioning enhanced BMSCs survival and regenerative properties: downregulated inflammatory genes and reduced expression of inflammatory factors, enhanced expression, and release of trophic/growth factors | Wei et al. (2012) |
| ICH (collagenase IV) | Adult male C57BL/6 mice (8–10 W, 25–28 g) | HP-BMSCs (tibias of post-natal day 21 Wistar rats), passage 5 | Intranasal injection | $1.0 \times 10^6$ cells | Promoted behavioral recovery | HP-BMSCs increased the expression of neurotrophic factors and enhances endogenous neurogenesis | Sun et al. (2015) |
| ICH (collagenase AOF type A) | Male C57BL/6J mice (7–9 W) | hAD-MSCs, passage 4 | Intravenous injection | $1.0 \times 10^6$ cells | Improved neurological deficits: ameliorates motor and cognitive function | hADSCs suppressed acute inflammation mediated by CD11b+CD45+ subpopulations | Kuramoto et al. (2019) |
| MCAO                | Female SD rats (14–16 W, 225–275 g) | aMSC$_{2Y}$ (femurs and tibias of SD rats < 4W) | Intravenous injection (retro-orbital sinus) | $5.0 \times 10^5$ cells/kg | Minimized the infarct and penumbra; improved functional recovery | aMSC$_{2Y}$ reversed the proinflammatory phenotype of microglia and reduce inflammatory signaling; induced OLs differentiation and myelination | Tobin et al. (2020) |
| Diseases model | Model animals | Origin of MSCs | Treatment route | Dose | Functions | Mechanisms | References |
|----------------|---------------|----------------|----------------|------|-----------|------------|------------|
| MCAO           | Male CX3CR1^GFP+/CCR2^FP+ mice (11–13 W, 22–26 g) | IL13-MSCs | Intracerebral injection | 5.0 × 10^6 cells | No obvious differences were observed | IL13-MSCs polarized both microglia and macrophages to a neuroprotective M2 phenotype during the pro-inflammatory status | Hamzei Taj et al. (2018) |
| ICH (collagenase VII) | Adult male SD rats (270–300 g) | MSCs, passage 10 | Intracerebral/ intravenous injection (CA/CV/LV) | 2.0 × 10^6 cells | Improved the motor function | MSCs differentiate into neurons, astrocytes and OLs | Zhang et al. (2006) |
| HI brain injury | C57BL/6 mouse pups (P9) | hMSCs, passage 3 | Intranasal injection | 1.0/2.0 × 10^6 cells | Improved sensorimotor function, promoted neuroregeneration, decreased lesion volume, reduced scar formation | hMSCs decreased microglia and astrocytes activity by secreting anti-inflammatory cytokines | Donega et al. (2014) |
| ICH (collagenase IV) | Adult male C57BL/6 mice (6–8 W, 22–25 g) | BMSCs (femurs and tibias of SD rats), passage 2–5 | Intracerebral injection (ipsilateral lesion area) | 2.0 × 10^6 cells | Attenuated brain water content, reduced hematoma volume, and improved neurological behavior impairment | BMSCs improve the anti-apoptotic ability of reactive astrocytes, trigger GFAP/VIM switch, and inhibit the final formation of the glial scar | Chen et al. (2020) |
| TBI            | Adult male SD rats (220–250 g) | BMSCs (from SD rats), passage 3–8 | Intravenous injection (jugular vein) | 4.0 × 10^6 cells | Improved neurological recovery; reduced brain water content | MSCs enhanced expression of TSG-6, and modulate inflammation-associated immune cells and cytokines | Zhang (2013) |
| ICH (collagenase IV) | Adult male SD rats (250–300 g) | BMSCs (femurs and tibias of 5-week-old SD rats), passage 3 | Intravenous injection (jugular vein) | 5.0 × 10^6 cells | Improved neurological deficits; reduced brain water content | TSG-6 produced by MSCs suppressed activation of the NF-κB signaling pathway and the degree of BBB leakage was decreased | Chen M. et al. (2015) |
| ICH (collagenase) | Adult male SD rats (12 W, 220 g) | HGF transduced hUC-MSCs, passage 4–6 | Intracerebral injection | 6.0 × 10^5 cells | Improved motor recovery (motor coordination and balance) | HGF-transduced MSCs enhance nerve fiber remyelination and axonal regeneration | Liu et al. (2010) |
| ICH (collagenase VII) | Adult male SD rats (190–210 g) | Flk-1^+ hBMSCs, passage 5 | Intracerebral injection (ipsilateral brain parenchyma) | 2.0 × 10^5 cells | Reduced brain edema; improved neurological function | Flk-1^+ hBMSCs reduced inflammatory infiltration, decreased cell apoptosis, and promoted angiogenesis | Bao et al. (2013) |
| ICH (collagenase VII) | Male SD rats (230–260 g) | hUC-MSCs | Intracerebral injection | 2.0 × 10^5 cells | Reduced injured lesion; accelerated functional recovery | hUC-MSCs inhibited inflammation and promoted angiogenesis | Liao et al. (2009) |
| ICH (autologous arterial blood) | Male Macaca fascicularis monkeys (4–6 years old, 4.0–4.4 kg) | hBMSCs, passage 6 | Intracerebral injection | 1.0–5.0 × 10^6 cells | Improved the recovery from ICH in a primate model | No mention | Feng et al. (2010) |
| ICH (collagenase IV) | Male SD rats (7 W, 240–280 g) | WJ-MSCs | Intracerebral injection (ipsilateral striatum) | 2.0 × 10^5 cells | Improved behavioral recovery | WJ-MSCs upregulated GDNF and increased differentiation into neuron-like cells | Lee et al. (2015) |

(Continued)
| Diseases model | Model animals | Origin of MSCs | Treatment route | Dose | Functions | Mechanisms | References |
|---------------|---------------|----------------|----------------|------|-----------|------------|------------|
| ICH (collagenase VII) | Adult male SD rats (250–300 g) | hUCB-MSCs | Intracerebral injection (left lateral ventricle) | $5.0 \times 10^5$ cells | Improve neurological recovery | hUCB-MSCs modulated the inflammatory environment, promoting neurogenesis and angiogenesis | Kim et al. (2015) |
| ICH (autologous blood) | Male SHR and WKY rats | BMSCs (femurs and tibias of 8-week-old SHRs), passage 3 | Intravenous injection (tail vein) | $2.0 \times 10^7$ cells | Enhanced neurological function recovery | BMSCs improved the integrity of the BBB | Wang C. et al. (2015) |
| ICH (collagenase VII) | Male SD rats (230–260 g) | hUC-MSCs, passage 3–6 | Intravenous/intracerebral injection | $2.0 \times 10^6$ cells | Improved neurological function and decreased injury volume | hUC-MSCs promoted angiogenesis | Xie et al. (2016) |
| ICH (collagenase IV) | Female adult Wistar rats (200–250 g) | BMSCs (femurs and tibias of Wistar rats) | Intracerebral injection (lesion zone) | $5.0 \times 10^6$ cells | Improved neurological function | Platelet-rich plasma-derived scaffolds increased the viability and biologic activity of BMSCs and optimize functional recovery | Vaquero et al. (2013) |
| ICH (collagenase VII) | Male SD rats (200–250 g) | AD-MSCs (adipose tissue of SD rats) | Intravenous injection (tail vein) | $2.0 \times 10^6$ cells | Improved functional recovery | AD-MSCs reduced cell death, increased cell proliferation, and upregulated levels of white matter-associated markers (NF, MBP, and Olig-2) leading to the restoration of white matter integrity | Otero-Ortega et al. (2015) |
| MCAO | Adult male SD rats (270–300 g), passage 3 | BMSCs (SD rats) | Intracerebral injection (left lateral ventricle) | $3.0 \times 10^3$ cells | Alleviated the WMI | BMSCs alleviated neuronal/axonal injury and promote the proliferation of OPCs and formation of the myelin sheath | Yu et al. (2018) |
| MCAO | Rat pups (P10) | MSCs | Intranasal injection | $1.0 \times 10^6$ cells | Improved long-term motor functional outcome | MSC enhanced white matter integrity | van Velthoven et al. (2017) |
| ICH (autologous blood) | Adult male Wistar rats (270–320 g) | hBMSCs | Intraarterial injection (internal carotid artery)/intravenous injection | $1.0 \times 10^6$ cells | Improved neurological functional outcome | hBMSCs improved histochemical parameters of neural regeneration and reduced the anatomical and pathological consequences of ICH | Seyfried et al. (2008) |
| ICH (collagenase VII) | Male ICR mice (7 W; 20–30 g), passage 4–11 | hBMSCs, passage 4–11 | Intracerebral injection (ipsilateral striatum) | $2.0 \times 10^5$ cells | Improved motor functional recovery | hBMSCs could be induced to differentiate mostly into neurons and a smaller number of astrocytes in vitro and in vivo and produce many neuroprotective factors | Nagai et al. (2007) |
TABLE 1 | Continued

| Diseases model | Origin of MSCs | Treatment route | Dose | Functions | Mechanisms | References |
|----------------|---------------|----------------|------|-----------|------------|------------|
| ICH (collagenase IV) | hAD-MSCs | Intravenous injection | 3.0 × 10^6 cells | Improved the functional outcome | hAD-MSCs activated the neuronal endogenous progenitor cells | Fatar et al. (2008) |
| Preterm WMI | hWJ-MSCs | Intranasal injection | 1.4 × 10^4 cells | Improved neurological recovery | hWJ-MSC prevented hypomyelination and microglia in a model of WMI in the premature rat brain | Oppliger et al. (2016) |

W, weeks; g, gram; ICH, intracerebral hemorrhage; WMI, white matter injury; MCAO, middle cerebral artery occlusion; IS, ischemic stroke; HI, hypoxic-ischemic; TBI, traumatic brain injury; MSCs, mesenchymal stem cells; BMSCs, bone marrow mesenchymal stem cells; hMSCs, human MSCs; hBMSCs, human BMSCs; HP-BMSCs, hypoxic preconditioned BMSCs; HUC-MSCs, human umbilical cord-derived MSCs; hADSCs, human adipose-derived stem cells; hADM-MSCs, human adipose-derived MSCs; hPMSCs, human placenta-derived MSCs; aMSCs, interleukin-γ-activated MSCs; WI-MSCs, Wharton’s jelly-derived MSCs; hUCB-MSCs, human umbilical cord blood-derived MSCs; Fik-1, fetal liver kinase 1; TkrB, tropomyosin receptor kinase B; EA, electroacupuncture; BDNF, brain-derived neurotrophic factor; NT4, neurotrophin-4/5; GAP-43, growth-associated protein-43; SD, Sprague-Dawley; Ols, oligodendrocytes; IL3, interleukin 13; CA, carotid artery; CV, cerebral vein; LV, lateral ventricle; GFAP, glial fibrillary acidic protein; VIM, vimentin; TSG-6, tumor necrosis factor (TNF-α) stimulated gene/protein 6; NF-κB, nuclear factor-κB; BBB, blood–brain barrier; HGF, hepatocyte growth factor; GDNF, glial cell line-derived neurotrophic factor; WKY rat, Wistar-Kyoto rat; SHR, spontaneously hypertensive rat; OPCs, oligodendrocyte progenitor cells.

autologous blood injection. It means that MSC transplantation alleviated axonal damage and enhanced synaptic plasticity to some extent. GAP-43 may be considered a potential therapeutic target for MSCs in the treatment of axonal injury following ICH.

The CST is the only descending conduction pathway, in which some axons directly take shape synapses with spinal motoneurons, evolved in the major system for skilled voluntary movement in human and motor functions in rodents. Motor deficits in a stroke critically lie in an interruption of CST integrity, i.e., the motor fibers descending from the cortex to the spinal cord (Hijioka et al., 2016; Jang et al., 2018; Chen W. et al., 2019). Our previous research detected WM degeneration which lasted for at least 5 weeks after ICH, i.e., even during the chronic phase following stroke (Ng et al., 2020). And the longitudinal pathological alternations of the CST in the cervical portion of the spinal cord after unilateral striatal hemorrhage in adult mice were first illustrated, implying that the structural integrity of the CST was compromised extensively after ICH (Ng et al., 2020). In general, the establishment of compensatory re-innervation in the bilateral hemispheres after brain injury is mainly achieved through axonal sprouting of surviving neurons, new synapse formation, and factors produced by the brain. MSCs have been reported to promote neurogenesis and to alleviate side effects in injured brain regions, where both differentiation and secretion of MSCs involve axonal plasticity. In addition to the neuroprotective and neurotrophic effects, Choi et al. (2018) proved that MSCs may also prevent hematoma expansion in the hyperacute stage of ICH by enhancing endothelial integrity of cerebral vasculature by uplifting the expression of tight junction proteins (ZO-1, occludin).

**Immunomodulating Properties of MSCs**

The scientific fact that neuroinflammation makes a principal contribution to the progress of ICH-induced brain damage is well acknowledged. Thus, modulating the immune response could help improve brain injury outcomes following ICH. The highly anti-inflammatory and immunomodulatory properties make MSCs suitable therapeutic candidates in inflammatory diseases, through regulating infiltration of microglia and neutrophils and increasing anti-inflammatory cytokines levels, while also downregulating the expression of proinflammatory cytokines.

Emerging knowledge in targeting neuroinflammation argues MSCs are effective modifiers of microglial phenotype by maintaining a resting, pro-regenerative microglial phenotype, or by controlling the microglial activation following stroke (Wei et al., 2012; Yan et al., 2013). Neurological deficits of collagenase-induced ICH-bearing mice during the subacute phase were improved by human adipose-derived stem cells (hADSCs) which suppressed the acute inflammation mediated by CD11b+ CD45+ cells subpopulations (Kuramoto et al., 2019). In a middle cerebral artery occlusion (MCAO) model of rats, microglia activation and inflammatory signaling were dramatically reduced by transplanted MSCs activated by interferon (INF)-γ, along with oligodendrogenesis and the minimization of the infarct and penumbra (Tobin et al., 2020). The activation of microglia is largely determined by CX3CR1, and MSCs are known to shift activated inflammatory M1 macrophages to an M2 macrophage-like phenotype through prostaglandin E2 (PGE2). In a global cerebral ischemia (GCI) mouse model conducted by Du et al. (2020), CX3CR1 downregulation markedly reduced activation of microglia and inflammatory responses and promoted the generation of mature OLs from OPCs, and thus protected myelin from ischemia-induced damage. Similarly, Hamzei Taj et al. (2018) transplanted the BMSCs line which was genetically engineered to express the anti-inflammatory cytokine IL-13 (further named as IL13-MSCs) to CX3CR1^ΔGFP/+ CCR2^ΔFP/+ knock-in fluorescent protein reporter mice to distinguish brain-resident microglia from infiltrated macrophages after ischemic stroke. They found the transplantation of IL13-MSCs shifted microglia and macrophages toward an anti-inflammatory, neuroprotective phenotype at 14 days after ischemia (Hamzei Taj et al., 2018). Compared with MSCs, IL13-MSCs were proven to...
| Diseases | Clinical trials | Time from onset | Trial design | Origin of MSCs | Application | Dose | Safety analysis | Efficacy analysis | Functional results | Side effects | Limitation | References |
|----------|-----------------|-----------------|-------------|----------------|-------------|------|-----------------|-------------------|-------------------|-------------|------------|-----------|
| IS       | Prospective, randomized, open-label, blinded-endpoint | Acute and chronic phase | Treatment, n = 40; control, n = 20. Follow-up, 3 months | Autologous MSCs preconditioned with early-phase stroke serum | Intravenous infusion | 1.0 x 10^6 cells/kg | Screening tests monitored vascular occlusion | Multimodal MRI and detailed functional assessments | Safe and feasible | Not mentioned | Short duration of the follow-up evaluation | Kim et al. (2013) |
| IS       | Phase IIa, prospective, randomized, double-blind, placebo-controlled, single-center, pilot | Acute phase (the first 2 weeks) | Treatment, n = 10; control (placebo or vehicle), n = 10. Follow-up, 2 years | Allogeneic MSCs from adipose tissue | Single intravenous infusion | 1.0 x 10^6 units/kg | AEs, SAEs, neurologic and systemic complications, tumor development | mRS; NIHSS; infarct size; biomarkers | (1) Safe and feasible; (2) significantly improved recovery in the early stages of stroke by repairing ischemic brain tissue | Not mentioned | Small sample size | Díez-Tejedor et al. (2014) |
| IS       | Phase II, prospective, randomized, controlled, observer-blinded | Subacute phase (30–90 days) | Treatment, n = 59; control, n = 59. Follow-up, 360 days | Allogeneic BMSCs | Four intrathecal infusions once a week | 1.0 x 10^6 cells/kg | AEs, Neurological worsening tumor formation or abnormal cell growth, routine tests | NIHSS; mRS; mIBI; FMA, ARAT, and MWS; MoCA; infarction volume; tissue metabolism; fiber tract of the injured brain; the level of biomarkers | Safe and feasible | Not mentioned | Not mentioned | Deng et al. (2019) |
| IS       | Phase I/II, multi-center, open-label | Chronic phase (>6 months) | Phase 1, N = 15; phase 2, N = 21. Follow-up, 1 year | Allogeneic ischemia-tolerant MSCs | Single intravenous infusion | Phase 1: 0.5/1.0/1.5 x 10^6 cells/kg; phase 2: 1.5 x 10^6 cells/kg | AEs | NIHSS, BI, Mini-Mental Status Exam, Geriatric Depression Scale scores | (1) Safe and feasible; (2) behavioral gains | Infections, vascular disorders, and pain syndromes, unrelated or unlikely related to the investigational product; urinary tract infection and intravenous site irritation | Uncontrolled design; Mechanism of action was not studied; no appropriate training | Levy et al. (2019) |
| Diseases | Clinical trials | Time from onset | Trial design | Origin of MSCs | Application | Dose | Safety analysis | Efficacy analysis | Functional results | Side effects | Limitation | References |
|----------|-----------------|-----------------|-------------|----------------|-------------|------|----------------|-------------------|-------------------|-------------|-----------|------------|
| IVH      | Phase I, open-label, single-arm, single-center | 23–34 weeks | No control, Premature infants, N = 9 | Allogeneic hUCB-MSCs | Single intraventricular infusion | 3 received 5.0 × 10⁶ cells/kg, 6 received 1.0 × 10⁷ cells/kg | SAEs, DLT, MRI, death after transplantation, anaphylactic shock | Cranial ultrasonography, biomarkers | Safe and feasible | Inguinal hernia, late-onset sepsis, and meningitis. These SAEs are not directly related to MSCs | Small sample size, uncontrolled design | Ahn et al. (2018) |
| Stroke   | Phase 1/2a small-scale, open-label, dose-escalation | Chronic phase | No control, Treatment, N = 18, Follow-up, 1 year | Modified BMSCs (SB623) | Stereotactic implantation | 3 cohorts: 2.5/5.0/10.0 × 10⁶ cells | TEAEs NIHSS, MRI, FM total score, and FM motor function total score | (1) Safe and well-tolerated; (2) significant improvement in neurological function | Safe and feasible | All patients experienced at least 1 TEAE. None were related to cell treatment | Small sample size; non-randomized, uncontrolled design | Steinberg et al. (2016) |
| IS       | Prospective, single-center, open-label, blinded-endpoint randomized controlled | Subacute phase, <2 weeks following moderate-severe ischemic carotid stroke | Treatment, n = 16; control, n = 15, Follow-up, 2 years | Autologous BMSCs | Single intravenous infusion | 1.0/3.0 × 10⁸ cells/kg | AEs NIHSS, mRS, BI, ITT, LMM, motor FM score, task-related fMRI | (1) Safe and feasible; (2) improve motor recovery through sensorimotor neuroplasticity | 10 and 16 AEs in treated patients, and 12 and 24 in controls at 6-month and 2-year follow-up, respectively | Safe and feasible | Use of autologous MSCs; no sample size justification for the primary endpoint; small sample size | Jaillard et al. (2020) |
| IS       | Phase I, open-label, uncontrolled, dose-response, pilot | Acute phase | No control, Treatment, N = 6, Follow-up, 1 year | Novel Bone marrow stem cell (RAINBOW): autologous BMSC product HUNS001–01 | Intraparenchymal infusion | 3 received 2.0 × 10⁶ cells; 3 received 5.0 × 10⁷ cells | AEs NIHSS, mRS, BI, FM, MRI, FDG-PET, IMZ-SPECT | Safe and feasible | No AE | Small sample size; uncertain time point of cell administration | Shichinohe et al. (2017) |
| ICH      | Prospective | 5–7 days | Treatment, n = 60; control, n = 40, Follow-up, 6 months | BMSCs | Intracerebral injection (perihemor rhage area in the base ganglia) | Median number of MSCs: 9.47 × 10⁵/L (range, 7.25 × 10⁵ to 1.35 × 10⁶/L), 3.5 mL/patient | Cell viability, re-bleeding or infection, blood pressure control | Reduced neurological impairment and improved activities of daily living | Low grade fever; continuous dull chest pain 4 months after the implantation | Uncertain functional cell types; unclear effectiveness of mononuclear cell therapy in all ICH patients; experimental nature of the stem cell treatment | Li et al. (2013) |

(Continued)
| Diseases | Clinical trials | Time from onset | Trial design | Origin of MSCs | Application | Dose | Safety analysis | Efficacy analysis | Functional results | Side effects | Limitation | References |
|----------|----------------|----------------|-------------|----------------|-------------|------|----------------|-------------------|-------------------|-------------|------------|------------|
| IS       | Pilot          | Acute (<1 week); subacute (1 week to 1 month); stroke sequelae (0.5–2 years) | Treatment 1: N = 2, 1 dead; Treatment 2: N = 4, Follow-up, 2 years | Transplantation of NSPCs and UC-MSCs | Intravenous and intrathecal infusions | Treatment 1: 0.5 × 10⁶/kg, 4 times; Treatment 2: 1 with MSCs (0.5 × 10⁶/kg) + 3 with MSCs (5.0 × 10⁶/patient) and NSPCs (6.0 × 10⁶/patient) | Neurological deterioration or infection, tumorigenesis | NIHSS, mRS, BI, | (1) Safe and feasible; (2) improved the neurological functions, disability levels, and daily living abilities | Low-grade fever; minor dizziness | Small sample size; short duration of the follow-up evaluation; uncontrolled design | Qiao et al. (2014) |
| ICH/IS   | Pilot          | Within 3 months | No control. Treatment, N = 4, 3 with IS, 1 with ICH. Follow-up, 6 months | UC-MSCs | Single intra-artery infusion | 2.0 × 10⁷ cells | Angiography, MRI | mRS | (1) Safe and feasible; (2) improve the neurological function of IS patients with the MCA territory infarcts, but not ICH | No obvious AEs | Limited number of enrolled patients; short duration of the follow-up evaluation | Jiang et al. (2013) |
| IS       | Randomized open-labeled, observer-blinded | Acute phase | Treatment, n = 16, 4 dead; control, n = 36, 21 dead. Follow-up, 5 years | Autologous ex vivo cultured MSCs | Intravenous infusion | 5.0 × 10⁷ cells | Mortality, SAEs; immediate reaction | mRS, biomarkers, degree of involvement of the subventricular region of the lateral ventricle | (1) Long-term safe and feasible; (2) MSCs may improve recovery after stroke | No obvious AEs | Small sample size; not double-blinded; no exclusion of placebo effects | Lee et al. (2010) |
| IS       | Phase I, unblinded | Subacute or chronic phase | No control. Treatment, N = 12, patients with ischemic gray matter, white matter, and mixed lesions. Follow-up, 1 year | Auto serum-expanded autologous human MSCs | Single intravenous infusion | 0.6–1.6 × 10⁸ cells | AEs, MRI-tumorigenesis and abnormal cell growth | NIHSS; mRS; MRI; MRA; brain 3D CT angiography | Safe and feasible | Slight itching at the injection site; mild fever and nausea; slight appetite loss; no other obvious adverse events | Unblinded; No overall function or relative functional importance of different types of deficits; No mention of placebo effects or a contribution of recovery of the natural history of stroke | Honmou et al. (2011) |
| Diseases                  | Clinical trials     | Time from onset | Trial design | Origin of MSCs          | Application                | Dose                  | Safety analysis          | Efficacy analysis         | Functional results | Side effects | Limitation                                                                 | References       |
|---------------------------|---------------------|-----------------|--------------|--------------------------|----------------------------|-------------------------|-------------------------|--------------------------|------------------------|--------------|-----------------------------------------------------------------------------|------------------|
| ICH/IS Pilot              | Chronic             | No control. Treatment, $N = 10$, 6 with IS, and 4 with ICH. Follow-up, 6 months to 2 years | UC-MSCs, OECs, NPCs, Schwann cell | Intracranial/intravascular infusion | Mixed cells: UC-MSCs, $1.0/2.3 \times 10^7$ cells; | Clinic Neurologic Impairment Scale; BI | Clinic Neurologic Impairment Scale; BI | (1) Relatively clinically safe; (2) neurological function amelioration | No AE       | Small sample size; methodological limitations; incomplete outcome data; absence of environmental enrichment or cell-only treatment groups | Chen et al. (2013) |
| Stroke                    | Unblinded non-randomized experimental controlled | Treatment, $n = 20$; control, $n = 20$. Follow-up, 24 weeks | Autologous BMSCs | Intravenous infusion | 5.0–6.0 $\times 10^7$ cells | Routine laboratory tests | Strength, Tone (modified Ashworth), FM, Edinburgh handedness inventory, mBI, functional MRI scanning | (1) Safe and feasible. (2) Stem cells act as “scaffolds” for neural transplantation and may aid in repair mechanisms in stroke | No AE       | Small sample size; non-randomized design                                    | Bhasin et al. (2013) |
| Stroke                    | Non-randomized experimental controlled           | Treatment, $n = 6$; control, $n = 6$. Follow-up, 24 weeks | Autologous BMSCs | Intravenous infusion | 5.0–6.0 $\times 10^7$ cells | Routine laboratory tests, tumorigenesis, ectopic tissue formation, behavioral abnormality | FM, mBI, MRC, Ashworth tone grade scale scores, Functional imaging scans | Safe and feasible | No AE       | Small sample size; non-randomized design; limitation of dose of cells, site, and mode of transplantation | Bhasin et al. (2011) |
| TBI                       | Randomized, single-blind controlled              | Treatment, $n = 20$; control, $n = 20$. Follow-up, 6 months | UC-MSCs        | Lumbar puncture infusion | $1.0 \times 10^7$ cells | FM; FIM                  | FM; FIM                  | (1) Safe and feasible; (2) UC-MSCs improved the neurological function and self-care in patients with TBI sequels | Low intracranial pressure reactions (mild dizziness and headache) | Small sample size, a multicenter, and large sample size prospective randomized clinical trial is needed | Wang et al. (2013) |

ICH, intracerebral hemorrhage; IS, ischemic stroke; IVH, intraventricular hemorrhage; TBI, traumatic brain injury; MCA, middle cerebral artery; NSPCs, neural stem/progenitor cells; MSCs, mesenchymal stromal cells; BMSCs, bone marrow MSCs; UC-MSCs, umbilical cord-derived MSCs; hUCB-MSCs, human umbilical cord blood-derived MSCs; OEC, olfactory ensheathing cell; NPC, neural progenitor cell; NIHSS, National Institute of Health Stroke Scale; mRS, modified Rankin Scale; FM, Fugl Meyer assessment; BI, Barthel Index; mBI, modified Barthel Index; FIM, Functional Independence Measure; ITT, intent to treat analyses; LMM, linear mixed models analyses; MRI, magnetic resonance imaging; SPECT, single-photon emission computed tomography; FDG-PET, $^{18}$F-fluorodeoxyglucose positron emission tomography; IMZSPECT, $^{123}$I-iodomazenil single-photon emission computed tomography; AEs, adverse events; SAEs, serious AEs; TEAEs, treatment-emergent AEs; DLT, dose-limiting toxicity; MRA, magnetic resonance angiography; FIM, functional independence measures.
better limit oligodendrocyte loss and demyelination in a model for neuroinflammation and demyelination of cuprizone-treated mice, and promote histopathological and functional recovery in SCI of mice (Hamzei Taj et al., 2018). Engineered MSCs were also applied in malignant glioma tumor models (Sun et al., 2011).

As one of the main components of glial cells, astrocytes' regulation is also a promising target in WMI treatment (Zhang et al., 2006), although there is not adequate research recorded. Donega et al. (2014) reported that intranasal administration of human-MSC successfully reduced the expression of GFAP (a biomarker of astrocytes) and the formation of glial scars. Interestingly, in experiments conducted by Chen et al. (2020), transplanting BMSCs led to an elevation of GFAP level of expression; this difference might lie in the inherent double-edged features of activated astrocytes. Fortunately, the transplantation of MSCs into the CNS of ICH mice significantly improved cognitive and motor function and decreased hemorrhagic volume, which is consistent with previous research (Bedini et al., 2018). The key challenge in the treatment of ICH is to therefore understand how to magnify the advantages and minimize the disadvantage of reactive astrocytes. Another factor that presents a double-edged sword function due to producing both pro-inflammatory and anti-inflammatory cytokines is IL-33; it was proven that IL-33 improved wound healing through enhanced M2 macrophage polarization in diabetic mice (He et al., 2017). It is a member of the IL-1 family mainly expressed in astrocytes, microglia, and OLs in CNS (Schmitz et al., 2005). Besides, a late research voted for IL-33 as a neuroprotective target which shifted microglia polarization from M1 to M2 and thus promoted OLs differentiation and WM repair banding with its ligand ST2 after ICH (Chen Z. et al., 2019).

The immunomodulatory functions of MSCs can also be exerted by secreting multifunctional paracrine signaling factors (Zhang, 2013; Zhao et al., 2013; Liu et al., 2014; Zhou et al., 2019), including cytokines, growth factors, and chemokines, which combine to regulate the immune cells’ function. Systemically delivered MSCs can pass through the BBB while very few of these cells are detected homing to and survive in the lesion site of the brain (Chen et al., 2001). Functional activities are still improved by transplantation therapy. It has been commonly accepted that the functional benefits of MSCs’ transplantation are due to increased trophic support from these cells that reduce overall inflammation, thereby eliminating the potentially toxic environment (Caplan and Dennis, 2006; Hess and Borlongan, 2008). Some studies described the bystander mechanism of MSCs that MSCs is related to some soluble factors such as IL-10, indoleamine 2,3-dioxygenase (IDO), PGE2, transforming growth factor-β1 (TGF-β1), tumor necrosis factor-α (TNF-α), and TNF-α stimulated gene/protein 6 (TSG-6) (Nemeth et al., 2009). These molecules are encapsulated in cell-secreted extracellular vesicles (EVs), which are usually divided into exosomes, microvesicles (MVs), and apoptotic bodies according to the size and cell of origin. TSG-6 is an anti-inflammatory factor that can suppress neutrophil migration into the inflammation region, interact through the CD44 receptor on resident macrophages, and inhibit the NF-κB signaling pathway (Chen M. et al., 2015).

The BMSCs, injected from the jugular vein of ICH-bearing rats, attenuated the inflammatory response and decreased BBB disruption by secreting TSG-6 after being trapped in the lung (Chen M. et al., 2015). Most recently, researchers have verified the MSC-derived EVs (MSC-EVs), which mediate cell-to-cell inflammation and trophic signaling, to be feasible therapeutic targets for functional recovery after cortical injury in a monkey model (Medalla et al., 2020). Besides, MSC-EVs can also trigger macrophage polarization by increasing the formation of anti-inflammatory M2 phenotype over M1-like pro-inflammatory phenotype via downregulation of level of IL-23 and IL-22.

An in vitro experiment was performed which preclinically investigated the potential effect of MSCs on Treg and showed that MSCs induced the generation of Treg via epigenetic conversion of human conventional CD4 T cells, possibly partly through TGF-β and/or PD-1/PD-L1 pathway (Azevedo et al., 2020). PD-L1 was found to result in generating more Th2 and Treg cells but fewer Th1 and Th17 cells from naive CD4+ T cells via inhibiting the mTOR pathway in vitro experiment. Administrating PD-L1 could promote the development of Treg cells and inhibit the differentiation of Th17 cells and thus significantly alleviate symptoms and suppress disease progression in several murine models (Fujisawa et al., 2014; Ding et al., 2016; Han et al., 2017). Besides, PD-L1 usually promotes the phosphorylation of immune-receptor tyrosine and conveys negative modulation signals, leading to cell inactivation via STAT or Janus kinase (JAK). When the STAT1 phosphorylation was hampered, overexpressing PD-1/PD-L1 could decrease the M1 microglia, indicating a potential approach of transferring to the anti-inflammatory phenotype via inhibiting STAT1. The findings mentioned above may attract researchers to conduct further investigation on the specific mechanism and therapeutic effect of MSCs transplantation based on PD-1/PD-L1 after ICH.

Reducing Oxidative Stress

The antioxidative stress properties of MSCs have been validated in many previous studies (Shalaby et al., 2014), as diminishing ROS via the Nrf2 signaling pathway and protecting the body from oxidative stress was proven in many diseases such as acute lung injury (ALI), acute respiratory distress syndrome (ARDS), acute myocardial infarction (AMI), and acute liver failure (ALF). Various preconditioning strategies have been used to enhance the therapeutic efficacy of MSCs. Hypoxia preconditioning is thought to enhance MSCs’ survival and the expression of various trophic factors of MSCs, and even to strengthen the engraftment and paracrine properties (Hu and Li, 2018).

CONCLUSION AND PERSPECTIVES

For the past two decades, great progress in understanding the mechanisms of ICH-induced brain injury has been made (Balami and Buchan, 2012; Fang et al., 2013; Chen S. et al., 2015; Duan et al., 2016; Bobinger et al., 2018). But not until recently has the importance of WM damage in ICH, which exerts a high correlation with functional outcomes, been acknowledged. The
WM is involved in the transmission of motor and sensory information between the cerebral cortex and spinal cord. Therefore, whether in hemorrhagic or ischemic stroke, WM can cause serious cognitive dysfunction, emotional disorders, and motor disturbance. Without the parallel protection of WM, true lasting neurorestoration cannot be achieved.

Mesenchymal stem cells have proven to be an extremely promising therapy for WM due to their multipotency and self-renewal capacity. Furthermore, they exert reduced immunogenicity because of a low MHC class I expression and the absence of MHC class II molecules and co-stimulatory factors. Most importantly, MSCs can produce many immunomodulatory, neurotrophic, and angiogenic factors and have a potential immunomodulatory effect on immune cells (Caplan and Dennis, 2006; Chen et al., 2008; Bedini et al., 2018; Galipeau and Sensebe, 2018). And the neuroprotective effects have been well recognized in numerous pieces of research. To enhance the therapeutic effects of MSC transplantation by boosting the immunomodulatory properties of MSCs, investigators can also make some improvements to the MSC and the results show enhanced therapeutic effect, especially for the inflammatory modulation.

It is true that numerous signaling molecular pathways are involved in inflammatory responses and further exacerbate secondary brain damage (Zhou et al., 2014; Zhu et al., 2019). Although the modulation of immunological response after ICH showed promising results in a small proof-of-concept study, larger trials need to be done to further verify this. There are still several questions that remain to be addressed. First, studies in WMI are insufficient, whether effective drug targets of MSCs in the diseases mentioned above are equally effective in WM damage after ICH requires further verification. Second, human ICH pathomechanisms cannot be entirely mimicked by experimental models. The proportion of WM in rodent animals, especially in rats and mice, is much smaller than that of humans. It is essential to apply animals whose brain structures fit better with humans in future studies. Third, a majority of studies on post-ICH WM after ICH concentrate on single—factor intervention; agents with multiple targets or combined drug therapy strategies remain to be designed and tested in further research. Last but not least, cell resources, invasive extraction procedures, and cell quantity make future research of this therapy challenging. An improvement on MSCs calls for further investigation so that it can be better applied in ICH treatment.

AUTHOR CONTRIBUTIONS

The work presented here was carried out in collaboration with all authors. HS conceived and designed the review. JL wrote the manuscript. LX, DH, and YL helped with literature searching and summarizing. All authors read, commented on, and approved this manuscript.

FUNDING

This research was funded by the National Natural Science Foundation of China (81701243), Guangdong Basic and Applied Basic Research Foundation (2020A1515010038), the Pearl River S&T Nova Program of Guangzhou (201710010047), and the Presidential Foundation of Zhongguang Medical University (No. yzjj2018rc03).

ACKNOWLEDGMENTS

The support from the National Natural Science Foundation of China is gratefully acknowledged.

REFERENCES

Abbott, N. J., Patabendige, A. A., Dolman, D. E., Yusof, S. R., and Begley, D. J. (2010). Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13–25. doi: 10.1016/j.nbd.2009.07.030

Ahn, S. M., Kim, Y. R., Kim, H. N., Shin, Y. I., Shin, H. K., and Choi, B. T. (2016). Electroacupuncture ameliorates memory impairments by enhancing oligodendrocyte regeneration in a mouse model of prolonged cerebral hypoperfusion. Sci. Rep. 6:28646. doi: 10.1038/srep28646

Ahn, S. M., Kim, Y. R., Shin, Y. I., Ha, K. T., Lee, S. Y., Shin, H. K., et al. (2019). Therapeutic potential of a combination of electroacupuncture and TrkB-Expressing mesenchymal stem cells for ischemic stroke. Mol. Neurobiol. 56, 157–173. doi: 10.1007/s12035-018-1067-z

Ahn, S. Y., Chang, Y. S., Sung, S. I., and Park, W. S. (2018). Mesenchymal stem cells for severe intraventricular hemorrhage in preterm infants: phase I dose-escalation clinical trial. Stem Cells Transl. Med. 7, 845–856. doi: 10.1002/stem.17-0219

Aronowski, J., and Zhao, X. (2011). Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke 42, 1781–1786. doi: 10.1161/strokeaha.110.596718

Azevedo, R. L., Minskaia, E., Fernandes-Platzgummer, A., Vieira, A. I. S., da Silva, C. L., Cabral, J. M. S., et al. (2020). Mesenchymal stromal cells induce regulatory T cells via epigenetic conversion of human conventional CD4 T cells in vitro. Stem Cells 38, 1007–1019. doi: 10.1002/stem.3185

Babu, R., Bagley, J. H., Di, C., Friedman, A. H., and Adamson, C. (2012). Thrombin and hemin as central factors in the mechanisms of intracerebral hemorrhage-induced secondary brain injury and as potential targets for intervention. Neurosurg. Focus 32:E8. doi: 10.3171/2012.1.Focus13166

Bacmeister, C. M., Barr, H. J., McClain, C. R., Thornton, M. A., Nettles, D., Welle, C. G., et al. (2020). Motor learning promotes remyelination via new and surviving oligodendrocytes. Nat. Neurosci. 23, 819–831. doi: 10.1038/s41593-020-0637-3

Balami, J. S., and Buchan, A. M. (2012). Complications of intracerebral haemorrhage. Lancet Neurol. 11, 101–118. doi: 10.1016/s1474-4422(11)70264-2

Bao, X. J., Liu, F. Y., Lu, S., Han, Q., Feng, M., Wei, J. J., et al. (2013). Transplantation of Flk-1+ human bone marrow-derived mesenchymal stem cells promotes behavioral recovery and anti-inflammatory and angiogenesis effects in an intracerebral hemorrhage rat model. Int. J. Mol. Med. 31, 1087–1096. doi: 10.3892/ijmm.2013.1290

Bedell, B. J., and Narayana, P. A. (1998). Volumetric analysis of white matter, gray matter, and CSF using fractional volume analysis. Magn. Reson. Med. 39, 961–969. doi: 10.1002/mrm.1910390614

Bedini, G., Bersano, A., Zanier, E. R., Pischitetta, F., and Parati, E. A. (2018). Mesenchymal stem cell therapy in intracerebral haemorrhagic stroke. Curr. Med. Chem. 25, 2176–2197. doi: 10.2174/0929867325666180111101410
Bhasin, A., Srivastava, M. V., Kumaran, S. S., Mohanty, S., Bhatia, R., Bose, S., et al. (2011). Autologous mesenchymal stem cells in chronic stroke. Cerebrovasc. Dis. Extra 1, 93–104. doi: 10.1159/000333581
Bhasin, A., Srivastava, M. V., Mohanty, S., Bhatia, R., Kumaran, S. S., and Bose, S. (2013). Stem cell therapy: a clinical trial of stroke. Clin. Neurol. Neurosurg. 115, 1003–1008. doi: 10.1016/j.clineuro.2012.10.015
Bobinger, T., Burkardt, P., Huttner, H. B., and Manaenko, A. (2018). Programmed cell death after intracerebral hemorrhage. Curr. Pharmacopolar. 16, 1267–1281. doi: 10.2174/1570159X15666710602112851
Bradke, F., Fawcett, J. W., and Spira, M. E. (2012). Assembly of a new growth grabber in acute ischemic stroke. Ann. Neurol. 84, 260–273. doi: 10.1002/ana.22586
Deng, L., Peng, Q., Wang, H., Pan, J., Zhou, Y., Pan, K., et al. (2019). Intrathecal injection of algogenic bone marrow-derived mesenchymal stromal cells in treatment of patients with severe ischemic stroke: study protocol for a randomized controlled observer-blinded trial. Transl Stroke Res. 10, 170–177. doi: 10.1007/s12975-018-0634-y
Díez-Tejedor, E., Gutiérrez-Fernández, M., Martínez-Sánchez, P., Rodríguez-Frutos, B., Ruiz-Ares, G., Lara, M. L., et al. (2014). Reparative therapy for acute ischemic stroke with algogenic mesenchymal stem cells from adipose tissue: a safety assessment: a phase II randomized, double-blind, placebo-controlled, single-center, pilot clinical trial. J. Stroke Cerebrovasc. Dis. 23, 2694–2700. doi: 10.1016/j.jstrokecerebrovasdis.2014.06.011
Ding, Y., Han, R., Jiang, W., Xiao, J., Liu, H., Chen, X., et al. (2016). Programmed death ligand 1 plays a neuroprotective role in experimental autoimmune neuritis by controlling peripheral nervous system inflammation of rats. J. Immunol. 197, 3831–3840. doi: 10.4049/jimmunol.1601083
Donega, V., Nijboer, C. B., Braccioli, L., Slapar-Cortenbach, I., Kavelaars, A., van Bel, L., et al. (2014). Intranasal administration of human MSC for ischemic brain injury in the mouse: in vitro and in vivo neuroregenerative functions. PLoS One 9:e112339. doi: 10.1371/journal.pone.0112339
Du, B., Liang, M., Zheng, H., Fan, C., Zhang, H., Lu, X., et al. (2020). Anti-mouse CX3CR1 antibody alleviates cognitive impairment, neuronal loss and myelin deficits in an animal model of brain ischemia. Neuroscience 438, 169–181. doi: 10.1016/j.neuroscience.2020.05.011
Duan, X., Wen, Z., Shen, H., Shen, M., and Chen, G. (2016). Intracerebral hemorrhage, oxidative stress, and antioxidant therapy. Oxid. Med. Cell Longev. 2016:1203285. doi: 10.1155/2016/1203285
Ertl, J., Pichlbmerger, M., Tuca, A. C., Wurzer, P., Fuchs, J., Geyer, S. H., et al. (2018). Comparative study of regenerative effects of mesenchymal stem cells derived from placental amnion, chorion and umbilical cord on dermal wounds. Placenta 65, 37–46. doi: 10.1016/j.placenta.2018.04.004
Fafán-Labora, J. A., Morente-López, M., and Arufe, M. C. (2019). Effect of aging on behaviour of mesenchymal stem cells. World J. Stem Cells 11, 337–346. doi: 10.4252/wjsc.v11.i6.337
Fancy, S. P., Zhao, C., and Franklin, R. J. (2004). Increased expression of Nkx2.2 demyelination in the adult CNS. Neurobiol. Dis. 17, 983–986. doi: 10.1016/j.nbd.2004.06.015
Fang, H., Wang, P. F., Zhou, Y., Wang, Y. C., and Yang, Q. W. (2013). Toll-like receptor 4 signaling in intracerebral hemorrhage-induced inflammation and injury. J. Neuroinflammation 10:27. doi: 10.1186/1742-2094-10-27
Fatâr, M., Stroick, M., Griebe, M., Marwedel, I., Kern, S., Bieback, K., et al. (2008). Liposome-aptamer-derived adult mesenchymal stem cells improve functional outcome during intracerebral hemorrhage by proliferation of endogenous progenitor cells stem cells in intracerebral hemorrhages. Neurosci. Lett. 443, 174–178. doi: 10.1016/j.neulet.2008.07.077
Feng, M., Zhu, H., Zhu, Z., Wei, J., Lu, S., Li, Q., et al. (2010). Serial 18F-FDG PET demonstrates benefit of human mesenchymal stem cells in treatment of intracerebral hemorrhage: a translational study in a primate model. J. Nucl. Med. 51, 92–97. doi: 10.2967/jnumed.110.080325
Fu, Y., Hao, J., Zhang, N., Ren, L., Sun, N., Li, Y. J., et al. (2014). Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurol. 71, 1092–1101. doi: 10.1001/jamaneurol.2014.1065
Fujiiwara, H., Maeda, Y., Kobayashi, K., Nishimori, H., Matsuoka, K., Fuji, N., et al. (2014). Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease. J. Immunol. 193, 2565–2573. doi: 10.4049/jimmunol.1400954
Galipeau, J., and Sensebe, L. (2015). Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell 22, 824–833. doi: 10.1016/j.stem.2015.08.004
Cui, J., Cui, C., Cui, Y., Li, R., Sheng, H., Jiang, X., et al. (2017). Bone marrow mesenchymal stem cell transplantation increases GAP-43 Expression via ERK1/2 and PI3K/Akt pathways in intracerebral hemorrhage. Cell Physiol. Biochem. 42, 137–144. doi: 10.1159/000477122
Joseph, M. J. E., Caliaperumal, J., and Schlichter, L. C. (2016). After intracerebral hemorrhage, oligodendrocyte precursors proliferate and differentiate inside white-matter tracts in the rat striatum. *Transl. Stroke Res.* 7, 192–208. doi: 10.1007/s12975-015-0445-3

Joy, M. T., Ben Assayag, E., Shabashov-Stone, D., Liraz-Zaltsman, S., Mazitelli, J., Arenas, M., et al. (2019). CCR5 is a therapeutic target for recovery after stroke and traumatic brain injury. *Cell* 176, 1143.e13–1157.e13. doi: 10.1016/j.cell.2019.01.044

Kang, M., and Yao, Y. (2019). Oligodendrocytes in intracerebral hemorrhage. *CNS Neurol. Ther.* 25, 1075–1084. doi: 10.1111/cns13193

Keep, R. F., Hua, Y., and Xi, G. (2012). Intracerebral haemorrhage mechanisms of injury and therapeutic targets. *Lancet Neurol.* 11, 720–731. doi: 10.1016/s1474-4422(12)70104-7

Kim, K., Park, H. W., Moon, H. E., Kim, J. W., Bae, S., Chang, J. W., et al. (2015). The effect of human umbilical cord blood-derived mesenchymal stem cells in a collagenase-induced intracerebral hemorrhage rat model. *Exp. Neurobiol.* 24, 146–155. doi: 10.5607/en.2015.24.2.146

Kim, S. J., Moon, G. J., Chang, W. H., Kim, Y. H., and Bang, O. Y. (2013). Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial. *Trends Cereb. Med.* 13:137. doi: 10.1186/1745-6215-14-3-17

Kinzer, M., Hingerl, K., Konig, J., Reinsch, A., Strunk, D., Huppertz, B., et al. (2014). Mesenchymal stromal cells from the human placenta promote neovascularization in a mouse model in vivo. *Placenta* 35, 517–519. doi: 10.1016/j.placenta.2014.04.004

Kong, Y., and Lee, Y. (2011). Toll-like receptors in inflammation of the central nervous system. *Int. Immunopharmacol.* 11, 1407–1414. doi: 10.1016/j.intimm.2011.04.025

Konig, J., Weiss, G., Rossi, D., Wankhammer, K., Reinsch, A., Kinzer, M., et al. (2015). Placental mesenchymal stem cells derived from blood vessels or avascular tissues: what is the better choice to support endothelial cell function? *Stem Cells Dev.* 24, 113–131. doi: 10.1089/scd.2014.0115

Kuramoto, O., Takagi, T., Tatebayashi, K., Beppu, M., Doe, N., Fujita, M., et al. (2019). Intravenous administration of human adipose-derived stem cells ameliorates motor and cognitive function for intracerebral hemorrhage mouse model. *Brain Res.* 1711, 58–67. doi: 10.1016/j.brainres.2018.12.042

Kusano, Y., Seguchi, T., Horiuschi, T., Kakizawa, Y., Kobayashi, T., Tanaka, Y., et al. (2009). Prediction of functional outcome in acute cerebral hemorrhage using diffusion tensor imaging at 3T: a prospective study. *AJNR Am. J. Neuroradiol.* 30, 1561–1565. doi: 10.3174/ajnr.A1639

Lampron, A., Larochelle, A., Laflamme, N., Préfontaine, P., Plante, M. M., Sánchez, M. G., et al. (2015). Inefficient clearance of myelin debris by microglia impairs remyelinating processes. *J. Exp. Med.* 212, 481–495. doi: 10.1084/jem.20141656

Lee, H. S., Kim, S. K., Lim, H. S., Choi, M., Kim, H. K., Ahn, H. Y., et al. (2015). Priming Wharton’s jelly-derived mesenchymal stromal/stem cells with ROCK inhibitor improves recovery in an intracerebral hemorrhage model. *J. Cell Biochem.* 116, 310–319. doi: 10.1002/jcb.24969

Lee, J. S., Hong, J. M., Moon, G. J., Lee, P. H., Ahn, Y. H., and Bang, O. Y. (2010). A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. *Stem Cells Dev.* 28, 1099–1106. doi: 10.1002/stem.430

Levy, M. L., Crawford, J. R., Dib, N., Verkh, L., Tankovich, N., and Cramer, S. C. (2019). Phase I/II study of safety and preliminary efficacy of intravenous allogeneic mesenchymal stem cells in chronic stroke. *Stroke* 50, 2835–2841. doi: 10.1161/strokea19.02.6318

Li, Q., Weland, A., Chen, X., Lan, X., Han, X., Durham, F., et al. (2018). Ultrastructural characteristics of neuronal death and white matter injury in...
mouse brain tissues after intracerebral hemorrhage: coexistence of ferropothesis. Autophagy, and Necrosis. Front. Neurol. 9:581. doi: 10.3389/fneur.2018.00581
Li, Y., McIntosh, K., Chen, J., Zhang, C., Gao, Q., Borneman, J., et al. (2006). Allogenic bone marrow stromal cells promote glial-axonal remodeling without immunologic sensitization after stroke in rats. Exp. Neurol. 198, 313–325. doi: 10.1016/j.expneurol.2005.11.029
Li, Y., Wu, Q., Wang, Y., Li, L., Bu, H., and Bao, J. (2017). Senescence of mesenchymal stem cells (Review). Int. J. Mol. Med. 39, 775–782. doi: 10.3892/ijmm.2017.2912
Li, Z. M., Zhang, Z. T., Guo, C. J., Geng, F. Y., Qiang, F., and Wang, L. X. (2013). Synaptic localization of growth-associated protein Liao, W., Zhong, J., Yu, J., Xie, J., Liu, Y., Du, L., et al. (2009). Therapeutic benefit of human umbilical cord derived mesenchymal stromal cells in intracerebral hemorrhage rat: implications of anti-inflammation and angiogenesis. Cell Physiol. Biochem. 24, 307–316. doi: 10.1159/000323355
Liesz, A., Suri-Payer, E., Velkamp, C., Doerr, H., Sommer, C., Rivest, S., et al. (2009). Regulator T cells are key cell in cutaneous immune modulators in acute experimental stroke. Nat. Med. 15, 192–199. doi: 10.1038/nm.1927
Lim, J. Y., Park, S. I., Kim, S. M., Jun, J. A., Oh, J. H., Ryu, C. H., et al. (2011). Neural differentiation of bone-derived neurotrophic factor-expressing human umbilical cord blood-derived mesenchymal stem cells in culture via TrkB-mediated ERK and β-catenin phosphorylation and following transplantaion into the developing brain. Cell Transplant. 20, 1855–1866. doi: 10.3727/096368911X557236
Ling, H. P., Li, W., Zhou, M. L., Tang, Y., Chen, Z. R., and Hang, C. H. (2013). Expression of intestinal myeloid differentiation primary response protein 88 (Myd88) following experimental traumatic brain injury in a mouse model. J. Surg. Res. 179, e227–e234. doi: 10.1016/j.jsrs.2012.03.030
Liu, A. M., Lu, G., Tsang, K. S., Li, G., Wu, Y., Huang, Z. S., et al. (2010). Umbilical cord-derived mesenchymal stem cells with forced expression of hepatocyte growth factor enhance remyelination and functional recovery in a rat intracerebral hemorrhage model. Neurosurgery 67, 357–365. doi: 10.1227/01.NEU.0000371983.062783.d365-6
Liu, L., Yu, Y., Hou, Y., Chai, J., Duan, H., Chu, W., et al. (2014). Human umbilical cord mesenchymal stem cells transplantation promotes cutaneous wound healing of severe burned rats. PLoS One 9:e88348. doi: 10.1371/journal.pone.0088348
Lown, D. W., and Hafler, D. A. (2012). Regulatory T cells in the central nervous system. Immunol. Rev. 248, 156–169. doi: 10.1111/j.1600-0652.2011.01310.x
Lu, P., Woodruff, G., Wang, Y., Graham, L., Hunt, M., Wu, D., et al. (2014). Long-distance axonal growth from human induced pluripotent stem cells after spinal cord injury. Neuron 83, 789–796. doi: 10.1016/j.neuron.2014.07.014
McKernon, R. I., Schreiber, R. C., Rudge, J. S., and Silver, J. (1991). Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. J. Neurosci. 11, 3398–3411. doi: 10.1523/jneurosci.11-11-03398.1991
Medalla, M., Chang, W., Calderazzo, S. M., Go, V., Tsalas, A., Goodiffl, J. W., et al. (2020). Treatment with mesenchymal-derived extracellular vesicles reduces injury-related pathology in pyramidal neurons of monkey perilesional ventral premotor cortex. J. Neurosci. 40, 3385–3407. doi: 10.1523/JNEUROSCI.2226-19.2020
Mine, Y., Tatarishvili, J., Oki, K., Monni, E., Kokaia, Z., and Lindvall, O. (2013). Grafted human neural stem cells enhance several steps of endogenously generated neurogenesis and improve behavioral recovery after middle cerebral artery occlusion in rats. Neurobiol. Dis. 52, 191–203. doi: 10.1016/j.nbd.2012.12.006
Moll, G., Geißler, S., Catar, R., Ignatowicz, L., Hoogduijn, M. J., Strunk, D., et al. (2015). Cryopreserved or fresh mesenchymal stromal cells: only a matter of taste or key to unleash the full clinical potential of MSC therapy? Adv. Exp. Med. Biol. 951, 77–98. doi: 10.1007/978-3-319-45457-3_7
Morita, S., and Miyata, S. (2013). Synaptic localization of growth-associated protein 43 in cultured hippocampal neurons during synapogenesis. Cell Biochem. Funct. 31, 400–411. doi: 10.1002/cbf.2914
Nagai, A., Kim, W. K., Lee, H. J., Jeong, H. S., Kim, K. S., Hong, S. H., et al. (2007). Multilineage potential of stable human mesenchymal stem cell line derived from fetal marrow. PLoS One 2:e1272. doi: 10.1371/journal.pone.0001272
against oxidative stress in Escherichia coli-induced acute lung injury in mice. *Cytotherapy* 16, 764–775. doi: 10.1016/j.jcyt.2013.12.006

Shichinohe, H., Ishihara, T., Takahashi, K., Tanaka, Y., Miyamoto, M., Yamauchi, T., et al. (2013). Bone marrow stromal cells rescue ischemic brain by trophic effects and phenotypic change toward neural cells. *Neurorehabil. Neural. Repair.* 27, 80–89. doi: 10.1177/154596831348586

Shichinohe, H., Kawabori, M., Iijima, H., Teramoto, T., Abuminy, T., Nakayama, N., et al. (2017). Research on advanced intervention using novel bone marrow stem cell (RAINBOW): a study protocol for a phase I, open-label, uncontrolled, dose-response trial of autologous bone marrow stromal cell transplantation in patients with acute ischemic stroke. *BMJ. Neuroc.* 17:197. doi: 10.1186/s12883-017-0955-6

Smith, E. E., Gurok, M. E., Eng, J. A., Engel, C. R., Nguyen, T. N., Rosand, J., et al. (2004). White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. *Neurology* 63, 1606–1612. doi: 10.1212/01.wnl.0000142966.22886.29

Smith, H. K., and Gavins, F. N. (2012). The potential of stem cell therapy for stroke: is PISCES the sign? *Pflügers Jahrb. 26, 2239–2252.* doi: 10.1007/jf11-195719

Song, N., Scholtemeijer, M., and Shah, K. (2020). Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. *Trends Pharmacol. Sci.* 41, 653–664. doi: 10.1016/j.tips.2020.06.009

Steinberg, G. K., Kondziolka, D., Wechsler, L. R., Lunsford, L. D., Coburn, M. L., Billigen, J. B., et al. (2016). Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a phase 1a/2a study. *Stroke* 47, 1817–1824. doi: 10.1161/strokeaha.116.012995

Sun, X. L., Xu, Z. M., Ke, Y. Q., Hu, C. C., Wang, S. Y., Ling, G. Q., et al. (2020). Intranasal delivery of hypoxia-preconditioned bone marrow-derived mesenchymal stem cells enhanced regenerative effects after intracerebral hemorrhagic stroke in mice. *Exp. Neurol.* 272, 78–87. doi: 10.1016/j.expneuro.2015.03.011

Sun, X. L., Xu, Z. M., Ke, Y. Q., Hu, C. C., Wang, S. Y., Ling, G. Q., et al. (2011). Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells. *Cancer Lett.* 312, 168–177. doi: 10.1016/j.canlet.2011.07.035

Suzuki, T., Kohyama, K., Moriyama, K., Ozaki, M., Hasegawa, S., Ueno, T., et al. (2020). Extracellular ADP augments microglial inflammation and NF-κB activation via the P2Y12 receptor. *Eur. J. Immunol.* 50, 205–219. doi: 10.1002/ eji.201848013

Tan, F., Wang, J., Liu, J. X., Wang, C., Li, M. D., and Gu, Y. (2018). Electrococpuncture stimulates the proliferation and differentiation of endogenous neural stem cells in a rat model of ischemic stroke. *Exp. Ther. Med.* 16, 4943–4950. doi: 10.3892/etm.2018.6848

Tobin, M. K., Stephen, T. K., Lopez, K. L., Pergande, M. R., Bartholomew, A. M., Cologna, S. M., et al. (2020). Activated mesenchymal stem cells induce recovery following stroke via regulation of inflammation and oligodendrogenesis. *J. Am. Heart Assoc.* 9:e013583. doi: 10.1161/jaha.119.013583

Tolar, J., Le Blanc, K., Keating, A., and Blazar, B. R. (2010). Concise review: hitting the right spot with mesenchymal stromal cells. *Frontiers in Aging Neuroscience* | www.frontiersin.org 20 April 2021 | Volume 13 | Article 632054

Tse, W. T., Pendleton, J. D., Beyer, W. M., Egalka, M. C., and Guinan, E. C. (2003). Increased threshold of short-latency motor evoked potentials in transgenic mice expressing Channelrhodopsin-2. *PLoS One* 8:e178803. doi: 10.1371/journal.pone.0178803

Xiao, L., Zheng, H., Li, J., Wang, Q., and Sun, H. (2020). Neuroinflammation mediated by NLRP3 inflammasome after intracerebral hemorrhage and potential therapeutic targets. *Mol. Neurobiol.* 57, 5130–5149. doi: 10.1007/ s12035-020-02082-2

Xie, J., Wang, B., Wang, L., Dong, F., Bai, G., and Liu, Y. (2016). Intracerebral and intravenous transplantation represents a favorable approach for application of human umbilical cord mesenchymal stem cells in intracerebral hemorrhage mice. *Stem. Cell. Monit.* 22, 3552–3561. doi: 10.1002/smc2.990512

Yan, K., Zhang, R., Sun, C., Chen, L., Li, P., Liu, Y., et al. (2013). Bone marrow-derived mesenchymal stem cells maintain the resting phenotype of microglia and inhibit microglial activation. *PLoS One* 8:e41166. doi: 10.1371/journal.pone.0084116

Yu, X., Wu, H., Zhao, Y., Guo, Y., Chen, Y., Dong, P., et al. (2018). Bone marrow mesenchymal stem cells alleviate brain white matter injury via the enhanced proliferation of oligodendrocyte progenitor cells in focal cerebral ischemic rats. *Brain Res.* 1680, 127–136. doi: 10.1016/j.brainres.2017.12.019

Zhang, R. (2013). Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury. *J. Neuroinflammation* 10:106.
Zhang, Z., Zhang, Z., Lu, H., Yang, Q., Wu, H., and Wang, J. (2017). Microglial polarization and inflammatory mediators after intracerebral hemorrhage. *Mol. Neurobiol.* 54, 1874–1886. doi: 10.1007/s12035-016-9785-6
Zhao, X., Li, J., and Sun, H. (2019). CD200-CD200R interaction: an important regulator after stroke. *Front. Neurosci.* 13:40. doi: 10.3389/fnins.2019.00040
Zhao, X., Wang, H., Sun, G., Zhang, J., Edwards, N. J., and Aronowski, J. (2015). Neuronal Interleukin-4 as a modulator of microglial pathways and ischemic brain damage. *J. Neurosci.* 35, 11281–11291. doi: 10.1523/jneurosci.1685-15.2015
Zhao, Y., Gao, J., and Lu, F. (2013). Human adipose-derived stem cell adipogenesis induces paracrine regulation of the invasive ability of MCF-7 human breast cancer cells in vitro. *Exp. Ther. Med.* 6, 937–942. doi: 10.3892/etm.2013.1237
Zhou, K., Zhong, Q., Wang, Y. C., Xiong, X. Y., Meng, Z. Y., Zhao, T., et al. (2017). Regulatory T cells ameliorate intracerebral hemorrhage-induced inflammatory injury by modulating microglia/macrophage polarization through the IL-10/GSK3beta/PTEN axis. *J. Cereb. Blood Flow Metab.* 37, 967–979. doi: 10.1177/0271678X16648712
Zhou, Y., Wang, Y., Wang, J., Anne Stetler, R., and Yang, Q. W. (2014). Inflammation in intracerebral hemorrhage: from mechanisms to clinical translation. *Prog. Neurobiol.* 115, 25–44. doi: 10.1016/j.pneurobio.2013.11.003
Zhou, Y., Yamamoto, Y., Xiao, Z., and Ochiya, T. (2019). The immunomodulatory functions of mesenchymal stromal/stem cells mediated via paracrine activity. *J. Clin. Med.* 8:1025. doi: 10.3390/jcm8071025
Zhu, H., Wang, Z., Yu, J., Yang, X., He, F., Liu, Z., et al. (2019). Role and mechanisms of cytokines in the secondary brain injury after intracerebral hemorrhage. *Prog. Neurobiol.* 178:101610. doi: 10.1016/j.pneurobio.2019.03.003

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Li, Xiao, He, Luo and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.